USE OF MESENCHYMAL STEM CELLS IN REPAIRING MALE INFERTILITY SUFFERING FROM OLIGOSPERMIA. | ||||
| Journal of Productivity and Development | ||||
| Article 9, Volume 27, Issue 1, January 2022, Page 141-155 PDF (500.49 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/jpd.2022.221546 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Lamiaa El-Naggar  1; Timor Khalifa2; Bahgat Elfeky1
| ||||
| 1Genetic Engineering and Biotechnology Research Institute, University of Sadat City, Egypt. | ||||
| 2Faculty of Medicine, Azhar University, Egypt | ||||
| Abstract | ||||
| Germ cells must develop along distinct male paths to produce spermatozoa required for sexual reproduction. We show the expression of early germ cell markers cd105 in these cells. Mesenchymal stem cells (MSCs) are multipotent stem cells with abundant sources, active proliferation, and multidirectional differentiation potential. MSCs play a role through cell homing, secretion of active factors, and participation in immune regulation. Our findings provide direct evidence that human bone marrow cells and umbilical cord can differentiate to putative male germ cells and can provide a potential source of male germ cells that could sustain sperm production. This article summarizes the current research progress on mesenchymal stem cells in diseases related to infertility; advancements indicate that this emerging evidence contributes to solving problems related to male infertility. Furthermore, these data indicate the potential to harness the properties of stem cells for clinical applications and are also solve the problem of oligospermia persons and giving them absolve to become a normal person. According to count, before the injection the total number of cases were less than 15 million (100%), the mean was 6.04 ± 5.33 and after the injection of mesenchymal stem cells 8 cases (32%) were still less than 15 million but 17 cases (68%) were become more than 15 million, the mean was 23.02 ± 13.64, so p-value was <0.001 which is significant. Furthermore, According to vitality, before injection the minimum and maximum percent were (2%,28%, respectively), and also the mean was 13.0 ± 7.27. After the injection the minimum and maximum percent of vitality was (7,83%), the mean was 50.15 ± 25.47. Moreover, the p-value is less than 0.001, which is significant. Conclusively,the results from recent preclinical studies regarding stem cell-based therapies are promising. Stem cell-based therapies cast a new hope for infertility treatment as a replacement or regeneration strategy. | ||||
| Keywords | ||||
| Infertility; Mesenchymal stem cells; oligospermia; Stem cell | ||||
|
Statistics Article View: 233 PDF Download: 291 |
||||
